AAS
VOR icon

Ameritas Advisory Services’s Vor Biopharma VOR Stock Holding History

Ameritas Advisory Services’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37
Closed -$660 – 2134
2026
Q1 		$660 Buy
+37
New +$522 ﹤0.01% 1033

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Ameritas Advisory Services's VOR Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 37 shares — an estimated $660 sold.

Ameritas Advisory Services first reported a position in VOR in Q1 2026 and held it in 1 quarter. The position peaked at $660 in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 37 Vor Biopharma shares in Q2 2026, an estimated $660.
  • Ameritas Advisory Services first reported a position in Vor Biopharma in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Vor Biopharma position peaked at $660 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.